High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
The purpose of this study is to investigate whether high-dose icotinib treatment beyond disease progression is beneficial for NSCLC patients who have EGFR mutation and who have responded to EGFR TKI.
Carcinoma, Non-Small-Cell Lung
DRUG: Icotinib
Progression Free survival, 2 years
The purpose of this study is to investigate whether high-dose icotinib treatment beyond disease progression is beneficial for NSCLC patients who have EGFR mutation and who have responded to EGFR TKI.